Systems and carcinogenic impact assessment of topical microbicides on human mucosa
局部杀菌剂对人体粘膜的系统和致癌影响评估
基本信息
- 批准号:8922415
- 负责人:
- 金额:$ 69.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAddressAdverse effectsAnti-Inflammatory AgentsAnti-Retroviral AgentsAnti-inflammatoryApoptosisBiological AssayBiopsyCell DensityCell Differentiation processCell SurvivalCellsCervicalCervix UteriClinicalCross-Over TrialsDNADataDiphosphatesDoseDrug FormulationsEffectivenessEpithelial CellsFluorescenceForce of GravityFrequenciesGelGene ExpressionGene Expression ProfileGenital systemGilead brand of tenofovir disoproxil fumarateHIVHIV InfectionsHomeostasisHumanHuman PapillomavirusHuman papilloma virus infectionHuman papillomavirus 16ImmuneImmunodeficient MouseImpairmentIncidenceIndividualInflammationInflammation MediatorsInflammatoryInterleukin-10Intestinal NeoplasmsIrritantsLeadLeukocytesLicensureLocal MicrobicidesLongitudinal StudiesMalignant NeoplasmsMalignant neoplasm of cervix uteriMitochondriaModelingMucous MembraneMusMutationNeoplastic ProcessesNonoxynol 9OralPatientsPharmaceutical PreparationsPhasePhase III Clinical TrialsPlacebosPreventionPrevention strategyProliferatingProphylactic treatmentProteinsProteomePublishingRectumRegulatory PathwayRelative (related person)ResistanceReverse Transcriptase InhibitorsRiskRodentRouteSafetyScheduleSpecimenStimulusSuggestionSystemSystems BiologyT-LymphocyteTMC120-R147681TenofovirTestingThymidineTimeTissuesTopical applicationToxic effectTransgenic MiceVaginaVagina CarcinomaVaginal RingWomanXenograft procedureZidovudinearmcarcinogenesiscarcinogenicitycervicovaginalchemokinedesigndigitalds-DNAefficacy trialfollow-upin vitro Assayin vivoinnovationmicrobicidemouse modelneoplastic cellnovelnovel strategiesnucleoside analogphase 1 studypreventprotective efficacypublic health relevancerectalrepairedscreeningsexual HIV transmissiontooltumor
项目摘要
DESCRIPTION (provided by applicant): Several antiretroviral drugs are being tested as topical microbicides for the prevention of sexual HIV transmission. Because effective HIV prophylaxis would entail frequent use of topical antiretroviral drugs by healthy individuals, such use would need to be safe. However, in a recent comprehensive assessment of 1% tenofovir gel in vivo, conducted in the MTN-007 trial, we uncovered that it had profound effects on gene expression in the rectal mucosa, suggesting important changes in gut immune and self-repair homeostasis. When we followed up on these results using human primary vaginal epithelial cells, we found very similar changes. These changes, in particular pronounced impairment of mitochondrial function and the prospect of carcinogenicity, have the potential to contraindicate the use of tenofovir, and potentially of other drugs of the same DNA chain terminator class, as a topical microbicide. It is therefore imperative to extensively and immediately expand on these findings in order to corroborate tenofovir's side effects on the mucosa, to determine whether pericoital use is safer than daily use, and to compare its effects on the rectal and vaginal mucosa in vivo. In Aim 1 of this proposal we will address these issues using systems biology approaches in two trials testing 1% tenofovir gel, MTN-014 and MTN-017, using rectal and vaginal tissue specimens. Besides indirect suggestions in our data that tenofovir could increase neoplastic processes in the mucosa, a large body of data has demonstrated that DNA chain terminator drugs, like tenofovir and azidothymidine, are carcinogenic and mutagenic in a dose-dependent manner. Because of the potential gravity of this effect and the high concentrations of active drug achieved in mucosal tissues after topical application (>2 logs higher than achieved by oral dosing), we propose in Aim 2 to directly investigate the mucosal carcinogenicity of topical tenofovir and to determine whether non-DNA chain terminators like dapivirine might be safer alternatives. We propose innovative approaches designed to overcome the limitations of traditional rodent carcinogenicity models, incorporate human primary mucosal epithelial cells, and include an assessment of human papilloma virus (HPV) as a co-factor in tenofovir-induced carcinogenesis. These studies will help determine the relative suitability of drugs like tenofovir as topical prevention agents in comparison to non-DNA chain terminators like dapivirine, and provide novel tools for the assessment of the mucosal safety profile of candidate microbicide drugs, including the likelihood of carcinogenicity. Should our study confirm that DNA chain terminator drugs are too risky for mucosal application, it is hoped that we will find drugs like dapivirine to be effective and safer alternatives.
描述(由申请人提供):几种抗逆转录病毒药物正在测试作为局部杀微生物剂,用于预防性传播艾滋病毒。由于有效的艾滋病毒预防需要健康人经常使用局部抗逆转录病毒药物,因此这种使用需要安全。然而,在MTN-007试验中进行的1%替诺福韦凝胶体内综合评估中,我们发现它对直肠粘膜中的基因表达有深远的影响,表明肠道免疫和自我修复稳态的重要变化。当我们使用人类原代阴道上皮细胞跟踪这些结果时,我们发现了非常相似的变化。这些变化,特别是线粒体功能的明显损害和致癌性的前景,有可能禁忌使用替诺福韦,并可能禁忌使用相同DNA链终止剂类的其他药物作为局部杀微生物剂。因此,必须广泛和立即扩大这些发现,以证实替诺福韦对粘膜的副作用,以确定是否围产期使用比日常使用更安全,并比较其对体内直肠和阴道粘膜的影响。在本提案的目标1中,我们将使用系统生物学方法,在两项试验中使用直肠和阴道组织标本测试1%替诺福韦凝胶MTN-014和MTN-017,以解决这些问题。除了在我们的数据中间接暗示替诺福韦可能增加粘膜中的肿瘤过程之外,大量数据已经证明DNA链终止剂药物,如替诺福韦和叠氮胸苷,以剂量依赖性方式致癌和致突变。由于这种效应的潜在严重性和局部应用后粘膜组织中达到的高浓度活性药物(比口服给药高>2 log),我们在目标2中建议直接研究局部替诺福韦的粘膜致癌性,并确定非DNA链终止剂如达匹韦林是否可能是更安全的替代品。我们提出了创新的方法,旨在克服传统的啮齿类动物致癌性模型的局限性,纳入人原代粘膜上皮细胞,并包括评估人乳头瘤病毒(HPV)作为替诺福韦诱导的致癌作用的辅助因子。这些研究将有助于确定与非DNA链终止剂(如达匹韦林)相比,替诺福韦等药物作为局部预防剂的相对适用性,并为评估候选杀微生物剂药物的粘膜安全性提供新的工具,包括致癌性的可能性。如果我们的研究证实DNA链终止剂药物对粘膜应用风险太大,我们希望我们能找到像dapivirine这样的药物作为有效和更安全的替代品。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Florian Hladik其他文献
Florian Hladik的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Florian Hladik', 18)}}的其他基金
The push and pull of inflammation on HIV susceptibility: impact of host variation in CD101 and AXL
炎症对 HIV 易感性的推拉:CD101 和 AXL 宿主变异的影响
- 批准号:
10546199 - 财政年份:2022
- 资助金额:
$ 69.05万 - 项目类别:
Impact of the menstrual cycle on granulysin-mediated immunity in the human cervicovaginal tract
月经周期对人宫颈阴道颗粒溶素介导的免疫的影响
- 批准号:
10616798 - 财政年份:2022
- 资助金额:
$ 69.05万 - 项目类别:
Impact of the menstrual cycle on granulysin-mediated immunity in the human cervicovaginal tract
月经周期对人宫颈阴道颗粒溶素介导的免疫的影响
- 批准号:
10450305 - 财政年份:2022
- 资助金额:
$ 69.05万 - 项目类别:
The push and pull of inflammation on HIV susceptibility: impact of host variation in CD101 and AXL
炎症对 HIV 易感性的推拉:CD101 和 AXL 宿主变异的影响
- 批准号:
10664009 - 财政年份:2022
- 资助金额:
$ 69.05万 - 项目类别:
The regulatory role of natural progesterone in barrier immunity
天然黄体酮在屏障免疫中的调节作用
- 批准号:
10604809 - 财政年份:2022
- 资助金额:
$ 69.05万 - 项目类别:
The regulatory role of natural progesterone in barrier immunity
天然黄体酮在屏障免疫中的调节作用
- 批准号:
10708998 - 财政年份:2022
- 资助金额:
$ 69.05万 - 项目类别:
Vaginal immune effects of testosterone in transmasculine individuals
睾酮对跨男性个体的阴道免疫影响
- 批准号:
10369028 - 财政年份:2021
- 资助金额:
$ 69.05万 - 项目类别:
Cervicovaginal immune factors throughout the menstrual cycle: analysis of a cohort of Kenyan adolescents, systematic review, and meta-analysis
整个月经周期的宫颈阴道免疫因素:肯尼亚青少年队列分析、系统评价和荟萃分析
- 批准号:
10222496 - 财政年份:2020
- 资助金额:
$ 69.05万 - 项目类别:
Cervicovaginal immune factors throughout the menstrual cycle: analysis of a cohort of Kenyan adolescents, systematic review, and meta-analysis
整个月经周期的宫颈阴道免疫因素:肯尼亚青少年队列分析、系统评价和荟萃分析
- 批准号:
10046430 - 财政年份:2020
- 资助金额:
$ 69.05万 - 项目类别:
Extracellular vesicles in semen and genital HIV infection and immunity during heroin addiction and methadone or buprenorphine substitution therapy
海洛因成瘾和美沙酮或丁丙诺啡替代治疗期间精液中的细胞外囊泡和生殖器艾滋病毒感染和免疫
- 批准号:
9086328 - 财政年份:2015
- 资助金额:
$ 69.05万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 69.05万 - 项目类别:
Research Grant